Effect of a glucosamine-based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: A pilot study

Experimental and Therapeutic Medicine

Volumn 2, Issue 5, 2011, Pages 893-899

  Nakasone, Yasushi ^a   Watabe, Kazunori ^a   Watanabe, Keita ^b   Tomonaga, Akihito ^c   Nagaoka, Isao ^d   Yamamoto, Tetsuro ^e   Yamaguchi, Hideyo ^e  

^a Kenkoukazoku Inc   (Japan)

^b Kitashinyokohama Orthopedic Surgery   (Japan)

^c Tana Orthopedic Surgery   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

^e TTC Co Ltd   (Japan)

Author keywords

Antioxidant micronutrients; Chondroitin sulfate; Combination supplement; Glucosamine; Joint tissue biomarkers; Osteoarthritis

Indexed keywords

CHONDROITIN SULFATE; COLLAGEN TYPE 2; DIMETHYL SULFONE; GLUCOSAMINE; GUAVA EXTRACT; HYALURONIC ACID; PLACEBO; THIAMINE; VITAMIN D;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; JAPANESE; KNEE OSTEOARTHRITIS; MALE; PAIN ASSESSMENT; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 79960260953     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.298     Document Type: Article

References (59)

1. Ravenda V, Manette C, Lemmens R, Mariani AM, Struvay N and Reginster JY: Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clin Exp Res 19: 55-60, 2007.
2. Jinks C, Jordan K and Croft P: Osteoarthritis as a public health problem: the impact of developing knee pain on physical function in adults living in the community: (KNEST 3). Rheumatology (Oxford) 46: 877-881, 2007.
3. Yoshimura N, Muraki S, Oka H, Mabuchi A, En-Yo Y, Yoshida M, Saika A, Yoshida H, Suzuki T, Yamamoto S, Ishibashi H, Kawaguchi H, Nakamura K and Akune T: Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 27: 620-628, 2009.
4. Eccles M, Freemantle N and Mason J: North of England evidence-based guidelines development project: summary guidelines for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. North of England Non-steroidal Anti-inflammatory Drug Guidelines Development Group. BMJ 317: 526-530, 1998.
5. Wieland HA, Michaelis M, Kirschbaum BJ and Rudolphi KA: Osteoarthritis: an untreatable disease? Nat Rev Drug Discov 4: 331-344, 2005.
6. Rashad S, Revell P, Hemingway A, Low F, Rainford K and Walker F: Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 2: 519-522, 1989.
7. Adams ME, Lussier AJ and Peyron JG: A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of knee osteoarthritis. Drug Saf 23: 115-130, 2000.
8. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M and Kessler RC: Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280: 1569-1575, 1998.
9. Rao JK, Mihaliak K, Kroenke K, Bradley J, Tiemey WM and Weinberger M: Use of complementary therapies for arthritis among patients of rheumatologists. Am Intern Med 131: 409-416, 1999.
10. Astin JA: Why patients use alternative medicine: results of a national study. JAMA 279: 1548-1553, 1998.
11. Bellamy N and Buchanan WW: Outcome measurement in osteoarthritis clinical trials: the case for standardization. Clin Rheumatol 3: 293-305, 1984.
12. Lequesne M, Brandt K, Bellamy N, Moskowitz R, Menkes CJ, Pelletier JP and Altman R: Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol Suppl 41: 65-71, 1994.
13. Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G and Rovati LC: Glucosamine sulfate use and delay of progression of knee osteoarthritis. A 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 162: 2113-2123, 2002.
14. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE and Gossett C: Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357: 251-256, 2001.
15. McAlindon TE, La Valley MP, Gulin JP and Felson DT: Glucosa- mine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 283: 1469-1475, 2000.
16. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y and Reginster JY: Structural and symptomatic efficacy of glucosamine and chondroitin sulfate in knee osteoarthritis. A comprehensive meta-analysis. Arch Intern Med 163: 1514-1522, 2003.
17. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO III, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW and Williams HJ: Glucosamine, chondroitin sulfate and the two in combination for painful knee osteoarthritis. N Engl J Med 354: 795-808, 2006.
18. Natural Medicines Comprehensive Database. 8th edition. Therapeutic Research Faculty, Stockton, CA, 2006. http://www.naturaldatabase.com. (Accessed April 21, 2011).
19. Rosenbaum CC, O'Mathúna DP, Chavez M and Shields K: Antioxidants and anti-inflammatory dietary supplements for osteoarthritis and rheumatoid arthritis. Altern Ther Health Med 16: 32-40, 2010.
20. Loeser RF, Carlson CS, Del Carlo M and Cole A: Detection of nitrotyrosine in aging and osteoarthritic cartilage: correlation of oxidative damage with the presence of interleukin-1 beta and with chondrocyte resistance to insulin-like growth factor 1. Arthritis Rheum 46: 2349-2357, 2002.
21. Yudoh K, Nguyen T, Nakamura H, Hongo-Masuko K, Kato T and Nishioka K: Potential involvement of oxidative stress in cartilage senescence and development of osteoarthritis: oxidative stress induces chondrocyte telomere instability and down-regulation of chondrocyte function. Arthritis Res Ther 7: R380-R391, 2005.
22. Henrotin Y, Deby-Dupont G, Deby C, De Bruyn M, Lamy M and Franchimont P: Production of active oxygen species by isolated human chondrocytes. Br J Rheumatol 32: 562-567, 1993.
23. Henrotin Y, Deby-Dupont G, Deby C, Franchimont P and Emerit I: Active oxygen species, articular inflammation and cartilage damage. EXS 62: 308-322, 1992.
24. Martin JA and Buckwalter JA: Aging, articular cartilage chondrocyte senescence and osteoarthritis. Biogerontology 3: 257-264, 2002.
25. Usha PR and Naidu MU: Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Invest 24: 353-363, 2004.
26. Kim LS, Axelrod LJ, Howard P, Buratovich N and Waters RF: Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage 14: 286-294, 2006.
27. Ojewole JA: Antiinflammatory and analgesic effects of Psidium guajava Linn. (Myrtaceae) leaf acqueous extract in rats and mice. Methods Find Exp Clin Pharmacol 28: 441-446, 2006.
28. McAlindon TE, Jaques P, Zhang Y, Hannan MT, Aliabadi P, Weissman B, Rush D, Levy D and Felson DT: Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis? Arthritis Rheum 39: 648-656, 1996.
29. McAlindon TE, Felson DT, Zhang Y, Hannan MT, Aliabadi P, Weissman B, Rush D, Wilson PW and Jacques P: Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med 125: 353-359, 1996.
30. Rizkalla G, Reiner A, Bogoch E and Poole AR: Studies on the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 90: 2268-2277, 1992.
31. Poole AR, Kobayashi M, Yasuda T, Laverty S, Mwale F, Kojima T, Sakai T, Wahl C, El-Maadaway S, Webb G, Tchetina E and Wu W: Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. Ann Rheum Dis 61 (Suppl 2): S78-S81, 2002.
32. Bassleer C, Ravati L and Frachimont P: Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage 6: 427-434, 1998.
33. Piperno M, Reboul P, Hellio Le Graverand MP, Peschard MJ, Annefeld M, Richard M and Vignon E: Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage 8: 207-212, 2000.
34. Lipiello L, Woodward J, Karpman R and Hammand TA: In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Relat Res 381: 229-240, 2000.
35. Oegema TR, Deloria LB, Sandy JD and Hart DA: Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knee of young rabbits. Arthritis Rheum 46: 2495-2503, 2002.
36. Uebelhart D, Thonar EJ, Zhang J and Williams JM: Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cartilage 6 (Suppl 1): S6-S13, 1998.
37. Christgau S, Henrotin Y, Tankó LB, Rovati LC, Collette J, Bruyere O, Deroisy R and Reginster JY: Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulfate. Clin Exp Rheumatol 22: 36-42, 2004.
38. Cibere J, Thorne A, Kopec JA, Singer J, Canvin J, Robinson DB, Pope J, Grant E, Lobanok T, Ionescu M, Poole AR and Esdaile JM: Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. J Rheumatol 32: 896-902, 2005.
39. Mazières B, Hucher M, Zaïm M and Garnero P: Effect of chondroitin sulfate in symptomatic knee osteoarthritis: a multicentre, randomized, double-blind, placebo-controlled study. Ann Rheum Dis 66: 639-645, 2007.
40. Wells AF, Klareskog L, Lindblad S and Laurent TC: Correlation between increased hyaluronan localized in arthritic synovium and the presence of proliferating cells: a role for macrophage-derived factors. Arthritis Rheum 35: 391-396, 1992.
41. Vilim V, Vytásek R, Olejárová M, Machácek S, Gatterová J, Procházka B, Kraus VB and Pavelka K: Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage 9: 612-618, 2001.
42. Kellgren JH and Lawrence JS: Radiological assessment of osteoarthritis. Ann Rheum Dis 16: 494-502, 1957.
43. Akai M, Doi T, Fujino K, Iwaya T, Kurosawa H and Nasu T: An outcome measure for Japanese people with knee osteoarthritis. J Rheumatol 32: 1524-1532, 2005.
44. International Classification of Functioning, Disability and Health. World Health Organization, Geneva, 2001.
45. Akai M, Iwaya T, Kurosawa H, Doi T, Nasu T, Hayashi K and Fujino K: Development of new disease-specific QOL measure for patients with knee osteoarthritis. Japanese Knee Osteoarthritis Measure (JKOM). J Phys Med 16: 55-62, 2005.
46. Lewis B, Lewis D and Cumming G: The comparative analgesic efficacy of transcutaneous electric nerve stimulation and a non-steroidal anti-inflammatory drug for painful osteoarthritis. Br J Rheumatol 33: 455-460, 1994.
47. Pham T, Van der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T and Dougados M; OMERACT-OARSI: Outcome variables for osteoarthritis clinical trial: the OMERACT-OARSI set of responder criteria. J Rheumatol 30: 1648-1654, 2003.
48. Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P and Uebelhart D: Chondroitins 4 and 6 sulphate in osteoarthritis of the knee: a randomized, controlled trial. Arthiritis Rheum 52: 779-786, 2005.
49. Garnero P and Delmas PD: Biomarkers in osteoarthritis. Curr Opin Rheumatol 15: 641-646, 2003.
50. Kraus VB: Biomarkers in osteoarthritis. Curr Opin Rheumatol 17: 641-646, 2005.
51. Garnero P, Ayral X, Rousseau FC, Christgau S, Sandell LJ, Dougados M and Delmas PD: Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46: 2613-2624, 2002.
52. Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, Uitterlinden AG and Pols HA: A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 50: 2471-2478, 2004.
53. Poole AR, Ionescu M, Fitzcharles MA and Billinghurst RC: The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods 294: 145-153, 2004.
54. Sharif M, George E, Shepstone L, Knudson W, Thonar EJ, Cushnaghan J and Dieppe P: Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. Arthritis Rheum 38: 760-767, 1995.
55. Pavelka K, Forejtová S, Olejárová M, Gatterová J, Senolt L, Spacek P, Braun M, Hulejová M, Stovicková J and Pavelková A: Hyaluronic acid levels may have predictive value for the progression of knee osteoarthritis. Osteoarthritis Cartilage 12: 277-283, 2004.
56. Mazières B, Garnero P, Guéguen A, Abbal M, Berdah L, Lequesne M, Nguyen M, Sallles JP, Vignon E and Dougados M: Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum Dis 65: 354-359, 2006.
57. Ayral X, Pickering EH, Woodworth TG, Mackillop N and Dougados M: Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis - results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 13: 361-367, 2005.
58. Saari H, Sorsa T, Lindy O, Sumalainen K, Halinen S and Konttinen YT: Reactive oxygen species as regulators of human neutrophil and fibroblast interstitial collagenases. Int J Tissue React 14: 113-120, 1992.
59. Saari H, Konttinen YT, Friman C and Sorsa T: Differential effects of reactive oxygen species on native synovial fluid and purified human umbrical cord hyaluronate. Inflammation 17: 403-415, 1993.